Current Edition

Upcoming Events

Advertisement

news

Allergan’s eye drug stacks up against Lucentis, but wider market still iffy

Allergan on Thursday touted data from two late-stage trials that showed a drug it in-licensed from a Swiss biotech proved non-inferior to Lucentis in the treatment...
Continue Reading →
news

Allergan to sell off women’s health, anti-infective businesses

Allergan plans to sell its women's health and infectious disease units, aiming to shore up investor confidence and more narrowly focus the company amid a steady e...
Continue Reading →
news

Saunders: All options remain on the table for Allergan

Brief: Allergan CEO Brent Saunders said Monday the Irish pharma is considering a wide range of business options, including further divestitures or a split of the ...
Continue Reading →